UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
Retrieved on:
Monday, March 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Private Securities Litigation Reform Act, Risk, Adult, Fatigue, SEC, Urination, Cancer, Medicine, Neoplasm, Breast milk, Sodium bicarbonate, Technology, Twitter, UTUC, Patient Information Advisory Group, Trial of the century, Time, NDA, Ureter, Urine, Recurrence, Transitional cell carcinoma, Kidney, Nausea, Pain, View, Clothing, Perforation, Swelling, Female, Nephrectomy, Vomiting, NMIBC, Clinical trial, Growth, Urinary tract infection, Man, Urinary bladder, FDA, Patient, Birth, Abdomen, Company, Stomach, ATLAS, Skin, Bone marrow, Fever, Safety, Orphan drug, COVID-19, Arm, Transitional epithelium, Blood, TURBT, Water, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Mitomycin C, Mitomycins, JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ENVISION TRIAL, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ENVISION TRIAL, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.
The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
Key Points:
- The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
- You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
- JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005260/en/